Verona Pharma PLC Holding(s) in Company (4777G)
May 30 2017 - 2:02AM
UK Regulatory
TIDMVRP
RNS Number : 4777G
Verona Pharma PLC
30 May 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Verona Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
--------------------------------------------------------------- --------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
-------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
------------------------------------------------------------------- ----------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------- ----------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------- ----------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------- ----------------------------------
Other (please
specify):
--------------------------------------------------------- -------- ----------------------------------
3. Full name of person(s) Vivo Ventures VII, LLC
subject to the
notification obligation:
(iii)
----------------------------------------------------------- ------------------------------------------
4. Full name of shareholder(s) Vivo Ventures fund VII, LP
(if different from 3.):(iv) Vivo Ventures VII Affiliates
Fund, LP
----------------------------------------------------------- ------------------------------------------
5. Date of the transaction April 28, 2017
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- ------------------------------------------
6. Date on which issuer April 28, 2017
notified:
----------------------------------------------------------- ------------------------------------------
7. Threshold(s) that is/are 9.84% to 9.14% Change at Combined
crossed or Interest Level
reached: (vi, vii)
----------------------------------------------------------- ------------------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- ----------------------------------- ------------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights (x)
Shares Voting
Rights
------------- ---------------- ----------------- -------------- ----------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------- ------------ ------------- -------------- --------- ------------ ------------ -----------
Ordinary
GB00B06GSH43 5,047,877 5,047,877 5,047,877 5,047,877 4.83%
---------------- ----------------- -------------- --------- ------------ ------------ -----------
ADS
US925050106 0 0 4,507,040 4,507,040 4.31%
------------- ---------------- ----------------- -------------- --------- ------------ ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- -------------- --------------------------------- ------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
--------------- -------------- --------------- ---------------- ------------------------- -----------------------
Nominal Delta
--------------- -------------- --------------- ---------------- ------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
---------------------------------------------------- ----------------------------------------------------------------
9,554,917 9.14%
---------------------------------------------------- ----------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
-------------------------------------------------------------------
Vivo Ventures VII, LLC is the general partner of both
Vivo Ventures Fund VII, LP (VV Fund VII)
and Vivo Ventures VII Affiliates Fund, LP. (Affiliates
Fund VII). Accordingly, Vivo Ventures VII,
LLC may be deemed to have indirect beneficial ownership
of shares of the Issuer directly owned
by VV Fund VII and Affiliates Fund VII. As of the date
of this filing, VV Fund VII and Affiliates
Fund VII beneficially own 9,351,110 and 203,807 shares
of Common Stock respectively.
-------------------------------------------------------------------
Proxy Voting:
-------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
--------------------------------------------- --------------------
11. Number of voting rights proxy
holder will cease
to hold:
--------------------------------------------- --------------------
12. Date on which proxy holder will
cease to hold
voting rights:
--------------------------------------------- --------------------
13. Additional information:
--------------------------------------------- --------------------
14. Contact name: Vivo Capital, LLC
Attn: Cinthia Sheu
--------------------------------------------- --------------------
15. Contact telephone number: +1-650-688-0818
--------------------------------------------- --------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLPGUUWAUPMPUB
(END) Dow Jones Newswires
May 30, 2017 02:02 ET (06:02 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
